Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Inhibition of USP10 induces degradation of oncogenic FLT3

Abstract

Oncogenic forms of the kinase FLT3 are important therapeutic targets in acute myeloid leukemia (AML); however, clinical responses to small-molecule kinase inhibitors are short-lived as a result of the rapid emergence of resistance due to point mutations or compensatory increases in FLT3 expression. We sought to develop a complementary pharmacological approach whereby proteasome-mediated FLT3 degradation could be promoted by inhibitors of the deubiquitinating enzymes (DUBs) responsible for cleaving ubiquitin from FLT3. Because the relevant DUBs for FLT3 are not known, we assembled a focused library of most reported small-molecule DUB inhibitors and carried out a cellular phenotypic screen to identify compounds that could induce the degradation of oncogenic FLT3. Subsequent target deconvolution efforts allowed us to identify USP10 as the critical DUB required to stabilize FLT3. Targeting of USP10 showed efficacy in preclinical models of mutant-FLT3 AML, including cell lines, primary patient specimens and mouse models of oncogenic-FLT3-driven leukemia.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Targeted effects of HBX19818 and P22077 on Ba/F3 cells expressing mutant or wild-type FLT3.
Figure 2: Targeted and selective effects of HBX19818 and P22077 on mutant-FLT3-expressing human AML cells and investigation of the mechanism of ubiquitin-mediated degradation.
Figure 3: Investigation of DUB targets of HBX19818 and P22077.
Figure 4: Investigation of USP10 as a mediator of FLT3-ITD and wild-type FLT3.
Figure 5: Targeted effects of HBX19818 and P22077 on cells resistant to FLT3 kinase inhibitors.
Figure 6: Effects of the combination of HBX19818 with FLT3 kinase inhibitors and targeted effects of USP10 inhibition on mutant-FLT3-positive AML primary cells in vitro and in vivo.

References

  1. 1

    Hershko, A. The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle. Cell Death Differ. 12, 1191–1197 (2005).

    CAS  Article  Google Scholar 

  2. 2

    Clague, M.J., Coulson, J.M. & Urbé, S. Cellular functions of the DUBs. J. Cell Sci. 125, 277–286 (2012).

    CAS  Article  Google Scholar 

  3. 3

    Pickart, C.M. & Fushman, D. Polyubiquitin chains: polymeric protein signals. Curr. Opin. Chem. Biol. 8, 610–616 (2004).

    CAS  Article  Google Scholar 

  4. 4

    Heideker, J. & Wertz, I.E. DUBs, the regulation of cell identity and disease. Biochem. J. 465, 1–26 (2015).

    CAS  Article  Google Scholar 

  5. 5

    Clague, M.J. et al. Deubiquitylases from genes to organism. Physiol. Rev. 93, 1289–1315 (2013).

    CAS  Article  Google Scholar 

  6. 6

    Abdul Rehman, S.A. et al. MINDY-1 is a member of an evolutionarily conserved and structurally distinct new family of deubiquitinating enzymes. Mol. Cell 63, 146–155 (2016).

    CAS  Article  Google Scholar 

  7. 7

    Sowa, M.E., Bennett, E.J., Gygi, S.P. & Harper, J.W. Defining the human deubiquitinating enzyme interaction landscape. Cell 138, 389–403 (2009).

    CAS  Article  Google Scholar 

  8. 8

    Williams, S.A. et al. USP1 deubiquitinates ID proteins to preserve a mesenchymal stem cell program in osteosarcoma. Cell 146, 918–930 (2011).

    CAS  Article  Google Scholar 

  9. 9

    Ndubaku, C. & Tsui, V. Inhibiting the deubiquitinating enzymes (DUBs). J. Med. Chem. 58, 1581–1595 (2015).

    CAS  Article  Google Scholar 

  10. 10

    Atwal, R.S. et al. Kinase inhibitors modulate huntingtin cell localization and toxicity. Nat. Chem. Biol. 7, 453–460 (2011).

    CAS  Article  Google Scholar 

  11. 11

    Li, Z. & Rana, T.M. A kinase inhibitor screen identifies small-molecule enhancers of reprogramming and iPS cell generation. Nat. Commun. 3, 1085 (2012).

    Article  Google Scholar 

  12. 12

    Levis, M. FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? Hematology (Am. Soc. Hematol. Educ. Program) 2013, 220–226 (2013).

    Article  Google Scholar 

  13. 13

    Weisberg, E. et al. FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist. Updat. 12, 81–89 (2009).

    CAS  Article  Google Scholar 

  14. 14

    Stone, R.M. et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N. Engl. J. Med. 377, 454–464 (2017).

    CAS  Article  Google Scholar 

  15. 15

    Oshikawa, G., Nagao, T., Wu, N., Kurosu, T. & Miura, O. c-Cbl and Cbl-b ligases mediate 17-allylaminodemethoxygeldanamycin-induced degradation of autophosphorylated Flt3 kinase with internal tandem duplication through the ubiquitin proteasome pathway. J. Biol. Chem. 286, 30263–30273 (2011).

    CAS  Article  Google Scholar 

  16. 16

    Sargin, B. et al. Flt3-dependent transformation by inactivating c-Cbl mutations in AML. Blood 110, 1004–1012 (2007).

    CAS  Article  Google Scholar 

  17. 17

    Ritorto, M.S. et al. Screening of DUB activity and specificity by MALDI-TOF mass spectrometry. Nat. Commun. 5, 4763 (2014).

    CAS  Article  Google Scholar 

  18. 18

    Reverdy, C. et al. Discovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme. Chem. Biol. 19, 467–477 (2012).

    CAS  Article  Google Scholar 

  19. 19

    Chauhan, D. et al. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell 22, 345–358 (2012).

    CAS  Article  Google Scholar 

  20. 20

    Altun, M. et al. Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes. Chem. Biol. 18, 1401–1412 (2011).

    CAS  Article  Google Scholar 

  21. 21

    Liu, J. et al. Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13. Cell 147, 223–234 (2011).

    CAS  Article  Google Scholar 

  22. 22

    Yuan, J., Luo, K., Zhang, L., Cheville, J.C. & Lou, Z. USP10 regulates p53 localization and stability by deubiquitinating p53. Cell 140, 384–396 (2010).

    CAS  Article  Google Scholar 

  23. 23

    Kessler, B.M. Selective and reversible inhibitors of ubiquitin-specific protease 7: a patent evaluation (WO2013030218). Expert Opin. Ther. Pat. 24, 597–602 (2014).

    CAS  Article  Google Scholar 

  24. 24

    Weisberg, E. et al. Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells. PLoS One 6, e25351 (2011).

    CAS  Article  Google Scholar 

  25. 25

    Fan, Y.H. et al. USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis. Cell Death Dis. 4, e867 (2013).

    CAS  Article  Google Scholar 

  26. 26

    De Kouchkovsky, I. & Abdul-Hay, M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 6, e441 (2016).

    CAS  Article  Google Scholar 

  27. 27

    Martelli, M.P., Sportoletti, P., Tiacci, E., Martelli, M.F. & Falini, B. Mutational landscape of AML with normal cytogenetics: biological and clinical implications. Blood Rev. 27, 13–22 (2013).

    CAS  Article  Google Scholar 

  28. 28

    Weisberg, E. et al. Discovery and characterization of novel mutant FLT3 kinase inhibitors. Mol. Cancer Ther. 9, 2468–2477 (2010).

    CAS  Article  Google Scholar 

  29. 29

    Warkentin, A.A. et al. Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy. eLife 3, 03445 (2014).

    Article  Google Scholar 

  30. 30

    Lavagna-Sévenier, C., Marchetto, S., Birnbaum, D. & Rosnet, O. FLT3 signaling in hematopoietic cells involves CBL, SHC and an unknown P115 as prominent tyrosine-phosphorylated substrates. Leukemia 12, 301–310 (1998).

    Article  Google Scholar 

  31. 31

    Dexheimer, T.S. et al. Discovery of ML323 as a novel inhibitor of the USP1/UAF1 deubiquitinase complex. In Probe Reports from the NIH Molecular Libraries Program [Internet] (National Center for Biotechnology Information, 2010). Available at https://www.ncbi.nlm.nih.gov/books/NBK259186/.

  32. 32

    Báez-Santos, Y.M., St John, S.E. & Mesecar, A.D. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds. Antiviral Res. 115, 21–38 (2015).

    Article  Google Scholar 

  33. 33

    Kelly, L.M. et al. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood 99, 310–318 (2002).

    CAS  Article  Google Scholar 

  34. 34

    Matsuo, Y. et al. Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23). Leukemia 11, 1469–1477 (1997).

    CAS  Article  Google Scholar 

  35. 35

    Armstrong, S.A. et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 3, 173–183 (2003).

    CAS  Article  Google Scholar 

  36. 36

    Weisberg, E. et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 1, 433–443 (2002).

    CAS  Article  Google Scholar 

  37. 37

    Chou, T.C. & Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22, 27–55 (1984).

    CAS  Article  Google Scholar 

  38. 38

    Weisberg, E. et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7, 129–141 (2005).

    CAS  Article  Google Scholar 

  39. 39

    Montero, J. et al. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell 160, 977–989 (2015).

    CAS  Article  Google Scholar 

  40. 40

    Pan, R. et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 4, 362–375 (2014).

    CAS  Article  Google Scholar 

Download references

Acknowledgements

We thank D. Ye and S. Walker for their assistance with assessment of luciferase expression indicative of leukemia cell burden in the bone marrow of mice via the Bright-Glo luciferase assay system (Promega, Madison, Wisconsin, USA). Nomo-1, P31-FUJ and NB4 were obtained from G. Gilliland (Fred Hutchinson Cancer Research Center, Seattle, Washington, USA). MV4,11 cells were obtained from A. Letai (Dana-Farber Cancer Institute, Boston, Massachusetts, USA). The human FLT3-ITD-postive AML line MOLM14 was obtained from S. Armstrong (Dana-Farber Cancer Institute, Boston, Massachusetts, USA). PBMCs were generously provided by S. Treon and G. Yang (Dana-Farber Cancer Institute, Boston, Massachusetts, USA). Flag-HA-USP10 was a gift from the Wade Harper lab (Harvard Medical School, Boston, Massachusetts, USA). Work was funded by the Dana-Farber Cancer Institute Accelerator Fund (S.J.B. and E.L.W.), the Leukemia and Lymphoma Society (S.J.B. and E.L.W.), the Chleck Family Foundation (N.J.S.), the National Science Fellowship Graduate Research Fellowship Program (L.D.) and the and Claudia Adams Barr Award (S.J.B. and E.L.W.).

Author information

Affiliations

Authors

Contributions

E.L.W., S.J.B., N.S.G. and J.D.G. initiated the project, and E.L.W. and S.J.B. oversaw all aspects of the project. E.L.W., N.J.S., J.Y. and I.L. performed biochemical, proliferation, signaling, knockdown, overexpression and immunoprecipitation studies. S.B. and A.L. designed and performed mitochondrial priming experiments. A. Christie, A. Christodoulou and D.M.W. designed and performed primagraft studies. H.T. and P.C.G. designed and performed in vivo bioluminescence studies. M.S.R., V.D.C. and M.T. designed and performed MALDI-TOF DUB assays. S.A. performed flow cytometry experiments. A.N. performed gene-knockdown experiments. S.D.-P. and H.-S.S. were responsible for the generation of USP10 enzyme used in biochemical assays. L.D., C.M. and R.W. performed immunoblotting experiments. R.S. provided AML patient samples. M.S., D.C. and K.C.A. offered valuable scientific feedback and helped with the conception of the research reported in the paper. E.L.W. and S.J.B. wrote the manuscript with input from all other authors.

Corresponding authors

Correspondence to Ellen L Weisberg or Sara J Buhrlage.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Text and Figures

Supplementary Results, Supplementary Tables 2–7, Supplementary Figures 1–10, Supplementary Note 1. (PDF 1022 kb)

Life Sciences Reporting Summary (PDF 168 kb)

Supplementary Table 1

List of DUB inhibitors. (XLSX 188 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Weisberg, E., Schauer, N., Yang, J. et al. Inhibition of USP10 induces degradation of oncogenic FLT3. Nat Chem Biol 13, 1207–1215 (2017). https://doi.org/10.1038/nchembio.2486

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing